Related Experiment Video
Updated: Dec 17, 2025
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Advances in EGFR/HER2-directed clinical research on breast cancer
Louis W C Chow1, Erich F Lie2, Masakazu Toi3
1UNIMED Medical Institute, Hong Kong, China; Organisation for Oncology and Translational Research, Hong Kong, China.
Abstract:
The discovery of the HER2 molecules has embarked a series of investigations on the efficacy and safety of different types of anti-HER2 therapies for treating breast cancer, with the clinical pathway requiring a more detailed, more precise, and more dynamics therapeutic approaches due to the heterogeneity of the disease. As the "do more" and "do less" approaches are becoming more important to personalize treatment for early HER2-positive breast cancer, recent advances aim at tackling the advanced stage of the disease by using novel therapeutic agents and combination strategies. There are also important points of consideration on prognosis and choice of therapies, including HER2 gene copy number, HER2 heterogeneity, tissue biomarkers, blood-based biomarkers, and HER2 mutation and its treatment. Altogether, these could potentially play a vital role in the journey of HER2-positive breast cancer patient to achieve greater survival benefit and potentially a cure for the disease.
Insights
Advances in HER2-positive breast cancer treatment focus on personalized therapies. Novel agents and strategies address disease heterogeneity and aim for improved survival and potential cures.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The discovery of Human Epidermal growth factor Receptor 2 (HER2) molecules has spurred research into targeted therapies for breast cancer.
- The heterogeneity of HER2-positive breast cancer necessitates dynamic and precise therapeutic approaches.
- Personalized treatment strategies, including "do more" and "do less" paradigms, are crucial for early-stage disease management.
Purpose of the Study:
- To review recent advances in anti-HER2 therapies for breast cancer.
- To discuss the evolving landscape of treatment for advanced HER2-positive breast cancer.
- To highlight key factors influencing prognosis and therapeutic choices in HER2-positive breast cancer.
Main Methods:
- Review of current literature on HER2-positive breast cancer therapies.
- Analysis of novel therapeutic agents and combination strategies.
- Examination of prognostic and predictive biomarkers.
Main Results:
- Personalized treatment approaches are increasingly important for early HER2-positive breast cancer.
- Novel agents and combination strategies are being developed for advanced stages.
- Biomarkers such as HER2 gene copy number, heterogeneity, tissue and blood-based markers, and HER2 mutations are critical for treatment decisions.
Conclusions:
- Understanding disease heterogeneity is key to optimizing anti-HER2 therapy.
- Biomarker analysis plays a vital role in guiding treatment selection and improving patient outcomes.
- These advancements hold potential for greater survival benefits and cures for HER2-positive breast cancer patients.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...